This Article Full Text Full Text (PDF) Supplementary Data, Le Page et al Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Le Page, C. Articles by Mes-Masson, A.-M. PubMed PubMed Citation Articles by Le Page, C. Articles by Mes-Masson, A.-M. Related Collections Early Detection Early Detection: Biomarkers: Discovery, Methodology, Validation

BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer

¹ Centre de Recherche du Centre Hospitalier de l'Université de Montréal/Institut du Cancer de Montréal; Departments of ² Human Genetics, and ³ Medicine, and ⁴ The Research Institute of the McGill University Health Centre, McGill University; and ⁵ Division of Gynecologic-Oncology and ⁶ Department of Medicine, Université de Montréal, Montreal, Quebec, Canada

Requests for reprints: Anne-Marie Mes-Masson, Centre de Recherche du Centre Hospitalier de l'Université de Montréal/Institut du Cancer de Montréal, 1560 rue Sherbrooke est, Montreal, Quebec, Canada H2L 4M1. Phone: 514-890-8000, ext. 25496; Fax: 514-412-7703. E-mail: anne-marie.mes-masson{at}umontreal.ca

This study aims to identify reliable prognosis markers to predict patient outcome at surgery in high-grade serous epithelial ovarian cancer by a real-time quantitative PCR (RT-q-PCR)-based test. Seventeen tissue samples from serous epithelial ovarian cancer patients were screened by DNA microarray to identify genes differentially expressed between tumors from patients who relapsed within 18 months and tumors from patients showing no relapse or relapsed after 24 months after initial diagnosis. RNA expression of a subset of genes was validated by RT-q-PCR in the initial set of 17 samples. From these results, a refined list was selected and tested in independent samples from 41 serous. Expression was associated with time to relapse and clinical variables. Microarray analysis identified a profile of 34 differentially expressed genes. RT-q-PCR validated the expression profile of a subset of seven genes in the initial set of patients. Differential gene expression was also validated in an independent set of patients. Low BTF4 or GCS expression was strongly associated with poor outcome in Kaplan-Meier analysis (P < 0.05, log-rank test) and Cox univariate as well as in multivariate analyses with a higher hazard ratio than clinical variables, such as residual disease, age, stage, and grade. (Cancer Epidemiol Biomarkers Prev 2008;17(4):913–20)